[EN] PROTECTED CARBOXYLIC ACID-BASED METABOLITES FOR THE TREATMENT OF MITOCHONDRIA-RELATED DISEASES<br/>[FR] MÉTABOLITES PROTÉGÉS À BASE D'ACIDE CARBOXYLIQUE POUR LE TRAITEMENT DES MALADIES LIÉES AUX MITOCHONDRIES
申请人:NEUROVIVE PHARMACEUTICAL AB
公开号:WO2017060418A1
公开(公告)日:2017-04-13
The present invention provides novel cell-permeable carboxylic acid-based metabolites and cell permeable precursors thereof aimed at increasing ATP-production in mitochondria and thus, for use in medicine. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being malonate. The provision of the novel cell permeable carboxylic acid- based metabolites is envisaged to allow passage over the cellular membrane and thus the cell permeable metabolite can be used to enhance mitochondrial ATP-output.
本发明提供了一种新型的细胞可透过性的基于羧酸的代谢物及其细胞可透过性前体,旨在增加线粒体中的ATP产生,因此可用于医学。在真核细胞中产生和利用的ATP的主要部分来源于线粒体氧化磷酸化,这是一个由Kreb循环提供高能电子的过程。并非所有的Kreb循环中间体都能容易地透过细胞膜,其中之一就是丙二酸。提供这些新型的细胞可透过性的基于羧酸的代谢物预计将允许通过细胞膜,因此细胞可透过性的代谢物可用于增强线粒体的ATP产量。